Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters

Journal Article · Sat Dec 01 00:00:00 EST 1990 · International Journal of Radiation Oncology, Biology and Physics; (USA)

DOI:https://doi.org/10.1016/0360-3016(90)90370-Y· OSTI ID:6246462

Roeske, J C; Chen, G T; Atcher, R W; Pelizzari, C A; Rotmensch, J; Haraf, D; Montag, A; Weichselbaum, R R ^[1]

---

1. Michael Reese/Univ. of Chicago, IL (USA)

Dose distributions for normal and tumor tissues from intraperitoneally administered radiolabeled antibodies have been calculated for 90-Yttrium (90Y), 131-Iodine (131I), and 211-Astatine (211At). The dose calculations use data on the activity of intraperitoneal fluid administered, the percent injected dose/gm uptake by tumor, biological half life, and a model for diffusion of antibody/radionuclide complex into peritoneal tissues. Calculations are performed for planar and hemispherical tumor shapes, ranging in size to establish the influence of geometry on dose distribution. Calculations for tumor geometry obtained from biopsies are also performed. When the activity is concentrated on or near the tumor surface, the maximum dose to a planar tumor for a 20 mci administration of 90Y is approximately 60 Gy, and falls rapidly to 50% of this value within 1 mm. However, for a hemispherical tumor, the dose is a maximum of 26 Gy, with an average of approximately 20 Gy. The surface dose from 131I (130 mci) is 240 Gy, and diminishes to 20 Gy in .05 cm in the planar case, whereas a hemispherical tumor receives a dose of 90 Gy over a large fraction of the volume, with the distal portions receiving 40 Gy. The surface dose for an administration of 70 mci of 211 At is 450 Gy and decreases to 50% of this value in 30 microns. Both surface geometry and tumor size are important determinants in the heterogeneity of tumor dose, as are the dose administered, antibody uptake, biodistribution, and residence time factors. These initial studies suggest that the size of disease which may be effectively treated is much less than the range of the particle emitted by radiolabeled antibodies. Furthermore, therapy is ultimately limited by the degree to which the antibody/radionuclide complex can diffuse and permeate the tumor.

• OSTI ID: 6246462
• Journal Information: International Journal of Radiation Oncology, Biology and Physics; (USA), Vol. 19:6; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
NEOPLASMS
RADIOIMMUNOTHERAPY
PERITONEUM
RADIATION DOSE DISTRIBUTIONS
ASTATINE 211
BIOLOGICAL HALF-LIFE
CALCULATION METHODS
INTRAPERITONEAL INJECTION
IODINE 131
MONOCLONAL ANTIBODIES
RADIATION DOSES
YTTRIUM 90
ALPHA DECAY RADIOISOTOPES
ANTIBODIES
ASTATINE ISOTOPES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
ELECTRON CAPTURE RADIOISOTOPES
HEAVY NUCLEI
HOURS LIVING RADIOISOTOPES
IMMUNOLOGY
IMMUNOTHERAPY
INJECTION
INTAKE
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
MEDICINE
MEMBRANES
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
RADIOIMMUNOLOGY
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SEROUS MEMBRANES
THERAPY
YTTRIUM ISOTOPES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)